Pfizer Inc.

PFE Healthcare Drug Manufacturers General

Pfizer Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.6 billion, down 1.65% from fiscal 2024. In the quarter to June 2026, revenue grew 2.60%, EPS fell 107.8%, free cash flow grew 125.2% and total debt rose 2.26%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years; insiders bought in the last twelve months.

30.50 0.55 +1.84%
Market cap
$170.7B
P/E
40.1×
Fwd P/E
18.6×
Dividend yield
7.05%
F-score
6/9
Altman Z
2.03
Beneish M
−2.52
Dividend safety
28/100

Pfizer Inc. (PFE) EV/FCF

Alert me on EV/FCF

As of 30 October 2026, Pfizer Inc. (PFE) trades at a EV/FCF of 22.1×. Over the past ten years it has ranged from 8.4× (October 2021) to 59.9× (July 2024); the current reading is higher than 78% of that period.

EV/FCF, daily

Embed this chart

Annual newest first

Period EV/FCF Change
FY2025 23.3× 8.38%
FY2024 21.5× (62.19%)
FY2023 56.8× 377.05%
FY2022 11.9× 2.42%
FY2021 11.6× (42.98%)
FY2020 20.4× (19.27%)
FY2019 25.3× 26.50%
FY2018 20.0× 22.69%
FY2017 16.3× 4.34%
FY2016 15.6× 0.52%

Quarterly newest first

Period EV/FCF Change
Jun 2026 18.5× (23.81%)
Mar 2026 24.3× 4.44%
Dec 2025 23.3× 16.40%
Sep 2025 20.0× 24.94%
42 more quarters

Against its own ten years

Low 8.4× High 59.9×
Ten-year median 17.2×
Current reading's percentile 76

EV/FCF against peers

What EV/FCF is

EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))

The full definition of EV/FCF →

More on PFE